Glazier J J, Kiernan F J, Bauer H H, Fram D B, Primiano C A, Mitchel J F, Dougherty J E, McKay R G
Department of Internal Medicine, Hartford Hospital, University of Connecticut 06102, USA.
Cathet Cardiovasc Diagn. 1997 Jul;41(3):261-7. doi: 10.1002/(sici)1097-0304(199707)41:3<261::aid-ccd6>3.0.co;2-4.
Percutaneous treatment of thrombotic stenoses or total occlusions in aged saphenous vein bypass grafts is associated with a significant incidence of complications primarily related to distal embolization. The purpose of this study was to assess the efficacy of local urokinase delivery with the Dispatch catheter prior to balloon angioplasty and/or intragraft stent placement as a new technique of vein graft revascularization. Local urokinase delivery with the Dispatch catheter was performed in 15 saphenous vein grafts (mean age = 11.7 +/- 2.5 yr) in 13 patients with unstable or postinfarction angina. The target lesion was a total occlusion in 5 of the procedures and a severe vein graft stenosis in the remaining 10. In all cases, urokinase was administered directly to the site of the stenosis/occlusion via the Dispatch catheter at 0.5 cc/min and at a concentration of 30,000 units/cc. The mean urokinase infusion time for the 15 procedures was 33 +/- 10 min (range = 10-60 min) and the mean urokinase dose was 495,000 +/- 158,000 units (range = 150,000-900,000 units). Following Dispatch therapy, mean minimal lumen diameter increased from 0.34 +/- 0.32 to 1.81 +/- 0.78 mm (P < 0.01), mean TIMI flow increased from 1.9 +/- 1.4 to 2.8 +/- 0.8 (P < 0.06), and mean thrombus score was reduced from 2.3 +/- 0.6 to 0.3 +/- 0.8 (P < 0.01). Mild no reflow was noted in two cases, although no patient demonstrated angiographic evidence of gross distal embolization. One of the patients with no reflow also demonstrated a small increase in cardiac enzymes. Subsequent balloon angioplasty/stent placement was successful in 14 of the 15 procedures (93% success rate). This preliminary report suggests that pretreatment of thrombotic saphenous vein graft stenoses with local urokinase delivery via the Dispatch catheter may decrease intragraft thrombus and possibly decrease the incidence of vascular complications associated with percutaneous intervention. This technique may allow for recanalization of totally occluded vein grafts with large clot burdens by using significantly less urokinase and shorter drug administration times than conventional infusion protocols.
经皮治疗老年大隐静脉旁路移植血管的血栓性狭窄或完全闭塞与主要与远端栓塞相关的并发症发生率较高有关。本研究的目的是评估在球囊血管成形术和/或移植血管内支架置入术前,使用Dispatch导管局部递送尿激酶作为一种新的静脉移植血管再血管化技术的疗效。13例不稳定型或心肌梗死后心绞痛患者的15条大隐静脉移植血管(平均年龄=11.7±2.5岁)接受了使用Dispatch导管局部递送尿激酶的治疗。5例手术的目标病变为完全闭塞,其余10例为严重的静脉移植血管狭窄。在所有病例中,尿激酶通过Dispatch导管以0.5 cc/分钟的速度、30000单位/cc的浓度直接给药至狭窄/闭塞部位。15例手术的平均尿激酶输注时间为33±10分钟(范围=10 - 60分钟),平均尿激酶剂量为495000±158000单位(范围=150000 - 900000单位)。Dispatch治疗后,平均最小管腔直径从0.34±0.32毫米增加至1.81±0.78毫米(P<0.01),平均TIMI血流从1.9±1.4增加至2.8±0.8(P<0.06),平均血栓评分从2.3±0.6降至0.3±0.8(P<0.01)。2例出现轻度无复流现象,尽管没有患者有造影证据显示存在明显的远端栓塞。其中1例无复流患者的心肌酶也有小幅升高。15例手术中有14例(成功率93%)随后成功进行了球囊血管成形术/支架置入术。这份初步报告表明,通过Dispatch导管局部递送尿激酶对血栓性大隐静脉移植血管狭窄进行预处理,可能会减少移植血管内血栓形成,并可能降低与经皮介入相关的血管并发症发生率。与传统输注方案相比,该技术通过使用显著更少的尿激酶和更短的给药时间,可能实现对伴有大量血栓负荷的完全闭塞静脉移植血管的再通。